(All fields required)
Please enter a valid email.
Please enter your name.
What is : (So we know you are human.)
Please supply the correct answer.
Michael J. Absalon, MD, PhD Member, Division of Oncology
focuses on developing new therapies and combinations of therapies for pediatric leukemias and lymphomas. He is currently investigating the therapeutic potential of combining the new targeted drug sorafenib with conventional chemotherapy for relapsed AML.
Member, Division of Oncology
Assistant Professor, UC Department of Pediatrics
Relapsed leukemia; lymphoma
BS: Lewis and Clark College, Portland, OR, 1987.
PhD: Massachusetts Institute of Technology, Cambridge, MA, 1994.
MD: Oregon Health Sciences University, Portland, OR, 1998.
Fellowship: St. Jude Children's Research Hospital, Memphis, TN, 2005.
Absalon MJ, Smith FO. Treatment strategies for pediatric acute myeloid leukemia. Expert Opin Pharmacother. 2009 Jan;10(1):57-79. Absalon MJ, McCarville MB, Liu T, Santana VM, Daw NC, Navid F. Pulmonary nodules discovered during the initial evaluation of pediatric patients with bone and soft-tissue sarcoma. Pediatr Blood Cancer. 2008 Jun;50(6):1147-53.
Takagi M, Absalon MJ, McLure KG, Kastan MB. Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell. 2005 Oct 7;123(1):49-63.
Absalon MJ, Harding CO, Fain DR, Li L, Mack KJ. Leigh syndrome in an infant due to mitochondrial DNA depletion. Pediatr Neurology. 2001; 24:60-63.
Denise M. Adams, MD Marjory J. Johnson Chair of Vascular Tumor Translational Research
is a nationally recognized expert on vascular anomalies with a keen interest in rare vascular tumors and life threatening malformations. She leads a clinical and translational research program to develop new therapies for these conditions and currently is the PI of a clinical study of sirolimus, a mTOR inhibitor, in the treatment of complicated vascular anomalies, the first trial of a new therapy for these conditions.
Marjory J. Johnson Chair of Vascular Tumor Translational Research
Medical Director, Hemangioma and Vascular Malformation Program
Fellowship Director, Hematology / Oncology
Professor, UC Department of Pediatrics
Quarmyne MO, Gupta A, Adams DM. Lymphangiosarcoma of the thorax and thoracic vertebrae in a 16-year-old girl. J Clin Oncol. 2012 Oct;30(29):294-8.
Haggstrom AN, Beaumont JL, Lai JS, Adams, DM, Drolet BA, Frieden IJ, Garzon MC, Holland KE, Horii KA, Lucky AW, Mancini AJ, Metry DW, Morel KD, Newell BD, Nopper AJ, Siegel D, Swigonski NL, Cella D, Chamlin SL. Measuring the severity of infantile hemangiomas: instrument development and reliability. Arch Dermatol. 2012 Feb;148(2):197-202.
Fadell MF 2nd, Jones BV, Adams DM. Prenatal diagnosis and postnatal follow-up of rapidly involuting congenital hemangioma (RICH). Pediatr Radiol. 2011 Aug;41(8):1057-60.
Maugans T, Sheridan RM, Adams D, Gupta A. Cutaneous vascular anomalies associated with neural tube defects: nomenclature and pathology revisited. Neurosurgery. 2011 Jul;69(1):112-8.
Hammill AM, Wentzel M, Gupta A, Nelson S, Lucky A, Elluru R, Dasgupta R, Azizkhan RG, Adams DM. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer. 2011 Dec 1;57(6):1018-24.
Adams DM. Special considerations in vascular anomalies: hematologic management. Clin Plast Surg. 2011 Jan;38(1):153-60.
Duffy KJ, Runge-Samuelson C, Bayer ML, Friedland D, Sulman C, Chun R, Kerschner JE, Metry D, Adams D, Drolet BA. Association of hearing loss with PHACE syndrome. Arch Dermatol. 2010 Dec;146(12):1391-6. Drolet BA, Chamlin SL, Garzon MC, Adams D, Baselga E, Haggstrom AN, Holland KE, Horii KA, Juern A, Lucky AW, Mancini AJ, McCuaig C, Metry DW, Morel KD, Newell BD, Nopper AJ, Powell J, Frieden IJ. Prospective study of spinal anomalies in children with infantile hemangiomas of the lumbosacral skin. J Pediatr. 2010 Nov;157(5):789-94.
Lomenick JP, Reifschneider KL, Lucky AW, Adams D, Azizkhan RG, Woo JG, Backeljauw PF. Prevalence of adrenal insufficiency following systemic glucocorticoid therapy in infants with hemangiomas. Arch Dermatol. 2009 Mar;145(3):262-6.
Dickie B, Dasgupta R, Nair R, Alonso MH, Ryckman FC, Tiao GM, Adams DM, Azizkhan RG. Spectrum of hepatic hemangiomas: management and outcome. J Pediatr Surg. 2009 Jan;44(1):125-33.
Karen C. Burns, MD, MS Director, Cancer Survivorship Center
conducts research on cancer survivorship and serious late effects of cancer treatment, including obesity, heart problems, fertility issues, increased risk of second cancers, and long-term outcomes of cancer survivors. She is also leading development of a fertility preservation program for children and adolescents undergoing chemotherapy as well as other unique medical and support services for adolescent and young adult cancer patients.
Director, Cancer Survivorship Center
BA: University of Pennsylvania, Philadelphia, PA, 1995.
MD: Temple University, Philadelphia, PA, 1999.
Residency: Pediatrics, St. Christopher's Hospital for Children in Philadelphia, PA, 2002.
MS: Medical College of Wisconsin, 2005.
Fellowship: Medical College of Wisconsin, 2005.
Burns K, Broudreau C, Panepinto J. Attitudes Regarding Fertility in Adolescent Females Diagnosed with Cancer. J Pediatr Hematol Oncol. 2006 Jun;28(6): 350-354.
Burns K and Camitta B. Pyrite or True Gold? Journal of Pediatric Hematology/Oncology. 2005 May;27(5): 244.
Lionel M.L. Chow, MD, PhD Member, Cancer Biology and Neural Tumors Program
Member, Cancer Biology and Neural Tumors Program
St. Baldrick’s Foundation Scholar
Sontag Foundation Distinguished Scientist
Lionel Chow, MD, PhD, received his medical and graduate degrees from McGill University in Montreal, Canada, where his research focused on the regulation of T-lymphocyte signaling by the intracellular tyrosine protein kinases Lck and Csk.
Following his clinical training in pediatrics and pediatric hematology / oncology at the Hospital for Sick Children in Toronto, Canada, he moved to St. Jude Children’s Research Hospital in Memphis, Tenn., to pursue his research interests.
Chow's research interests have been centered on glioblastoma multiforme, a particularly devastating form of cancer in adults and children. His work has resulted in the development of a number of novel and robust laboratory models for this disease. Using these models and interfacing with clinical trials in the Neuro-Oncology Program as well as those from national consortia such as the Children's Oncology Group (COG) and the Pediatric Brain Tumor Consortium (PBTC), Chow’s laboratory will continue research in this area with the goals of better understanding the origins of this form of cancer and improving patient outcomes.
PhD: McGill University, Montreal, Quebec, Canada, 1996.
MDCM: McGill University, Montreal, Quebec, Canada, 1997.
Residency: The Hospital for Sick Children, University of Toronto, Toronto, Canada, 1997-2000.
Clinical Fellowship: The Hospital for Sick Children, University of Toronto, Toronto, Canada, 2000-2003.
Postdoctoral Fellowship: St. Jude Children’s Research Hospital, Memphis, TN, 2003-2009.Clinical Fellowship: St. Jude Children’s Research Hospital, Memphis TN, 2008-2009.
Certification: Pediatrics, 2000.
Hummel, TR, Chow, LML, Fouladi, M, and Franz, D. Pharmacotherapeutic management of pediatric astrocytomas: current and upcoming strategies. Pediatric Drugs 2013; 15:29-42.
Joshi, K, Banasavadi-Siddegowda, Y, Mo, X, Kim, SH, Mao, P, Kig, C, Nardini, D, Sobol, RW, Chow, LML, Kornblum, HI, Waclaw, R, Beullens, M, and Nakano, I. MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells. Stem Cells 2013; 31:1051-1063.
Zhong, Y, Wan, Y-W, Pang, K, Chow, LML, and Liu, Z. Digital sorting of complex tissues for cell type-specific gene expression profiles. BMC Bioinformatics 2013; 14:89.
Rafalski, VA, Ho, PP, Brett, JO, Ucar, D, Dugas, JC, Pollina, EA, Chow, LML, Ibrahim, A, Baker, SJ, Barres, BA, Steinman, L, and Brunet, A. Expansion of oligodendrocyte progenitor cells upon SIRT1 inactivation in the adult brain. Nature Cell Biol. 2013; 15:614-624.
Wojton, J, Chu, Z, Mathsyaraja, H, Meisen, WH, Denton, N, Kwon, C-H, Chow, LML, Palascak, M, Franco, R, Bourdeau, T, Thornton, S, Ostrowski, MC, Kaur, B, and Qi, X. Systemic delivery of SapC-DOPS has antiangiogenic and antitumor effects against glioblastoma. Mol. Ther. 2013; 21:1517-1525.
Chow LML, Endersby R, Zhu X, Rankin S, Qu C, Zhang J, Broniscer A, Ellison DW, Baker SJ. Cooperativity within and among Pten, p53 and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell. 2011;19:305-316.
Lavado A, Lagutin O, Chow LML, Baker SJ, Oliver G. Prox1 is required for granule cell maturation and intermediate progenitor maintenance during brain neurogenesis. PLoS Biol. 2010;8:e1000460.
Cicero SA, Johnson D, Reyntjens S, Frase S, Connell S, Chow LML, Baker SJ, Sorrentino BP, Dyer MA. Cells previously identified as retinal stem cells are pigmented ciliary epithelial cells. Proc Natl Acad Sci U S A. 2009 Apr;106(16):6685-90.
Weber T, Corbett MK, Chow LML, Valentine MB, Baker SJ, Zuo J. Rapid cell-cycle reentry and cell death after acute inactivation of the retinoblastoma gene product in postnatal cochlear hair cells. Proc Natl Acad Sci U S A. 2008;105(2):781-5.
Chow LML, Zhang J, Baker SJ. Inducible Cre recombinase activity in mouse mature astrocytes and adult neural precursor cells. Transgenic Res. 2008;17(5):919-28.
Biplab Dasgupta, PhD, MS Member, Cancer Biology and Neural Tumors Program
Associate Professor, UC Department of Pediatrics
Biplab Dasgupta, PhD, MS, completed his doctorate in molecular biology and immunology at the Indian Institute of Chemical Biology, Calcutta, and a postdoctoral fellowship at Washington University School of Medicine, Saint Louis. Dr. Dasgupta came to Cincinnati Children's Hospital Medical Center in August 2009 as an assistant professor of pediatrics within the University of Cincinnati College of Medicine. He is interested in understanding how neural cell / stem cell metabolic and energy status is linked to cell cycle, lineage commitment, differentiation and tumorigenesis. His other interests include genetic, developmental, post-translational, tissue- and stimuli–specific regulation of the subunits that constitute the AMP kinase complex.
PhD: Indian Institute of Chemical Biology, Calcutta, 2003.
Postdoctoral Fellowship: Washington University School of Medicine, Saint Louis.
Xiaona Liu, Rishi Raj Chhipa and Biplab Dasgupta*. The Selective AMPK inhibitor Compound C is a potent AMPK-independent anti-glioma agent. Mol Cancer Ther. *Corresponding author. 2014 Mar:13(3):596-605
Xiaona Liu, Rishi Raj Chhipa, Shabnam Pooya, Matthew Wortman, Sara Yachishin, Ashish Kumar, Lionel Chow, Xuan Zhou, Ying Sun, Brian Quinn, Christopher McPherson, Ronald Warnick, Adi Kendler, Sailendra Giri, Jeroen Poels, Koennard Nogra, Benoit Viollet, Gregory A. Grabowski and Biplab Dasgupta*. Novel mechanisms of mTOR and cdc25c regulation by AMPK agonists independent of AMPK. Proc Natl Acad Sc U S A. *Corresponding author. 2014 Jan 28;111(4):E435-44.
Karkare S, Chhipa RR, Anderson J, Liu X, Henry H, Gasilina A, Nassar N, Roychoudhury J, Clark JP, Kumar A, Pauletti GM, Ghosh PK, Dasgupta B*. Direct inhibition of Retinoblastoma phosphorylation by Nimbolide causes cell cycle arrest and suppresses glioblastoma growth. Clin Cancer Research. 2014 Jan 1:20(1):199-212.
Dasgupta B, Ju JS, Sasaki Y, Liu X, Jung SR, Higashida K, Lindquist D, Milbrandt J. The AMPK beta2 subunit is required for energy homeostasis during metabolic stress. Mol Cell Biol. 2012; 32: 2837-48. Cover article. *Corresponding author.
Dasgupta B, Milbrandt J. AMP-activated protein kinase phosphorylates retinoblastoma protein to control mammalian brain development. Dev Cell. 2009 Feb;16(2):256-70.
Dasgupta B, Milbrandt J. Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci U S A. 2007 Apr;24;104(17):7217-22.
Hegedus B, Dasgupta B, Shin JE, Emnett RJ, Hart-Mahon EK, Elghazi L, Bernal-Mizrachi E, Gutmann DH. Neurofibromatosis-1 regulates neuronal and glial cell differentiation from neuroglial progenitors in vivo by both cAMP- and Ras-dependent mechanisms. Cell Stem Cell. 2007 Oct 11;1(4):443-57.
Dasgupta B, Gutmann DH. Neurofibromin regulates neural stem cell proliferation, survival, and astroglial differentiation in vitro and in vivo. J Neurosci. 2005 Jun 8;25(23):5584-94.
Dasgupta B, Yi Y, Chen DY, Weber JD, Gutmann DH. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res. 2005 Apr 1;65(7):2755-60.
Dasgupta B, Li W, Perry A, Gutmann DH. Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. Cancer Res. 2005 Jan 1;65(1):236-45.
Mariko D. DeWire, MD
focuses on developing novel therapeutics to treat children with all central nervous system tumors including young children (less than 4 years of age), very poor prognosis tumors such as high-grade gliomas and diffuse intrinsic pontine gliomas. Additionally, she has an interest in maximizing the quality of life in children and young adults diagnosed with brain tumors.
Mariko D. DeWire, MD, completed her graduate medical training at the Boonshoft School of Medicine at Wright State University, residency training in pediatrics at Lebonheur Children's Medical Center, and pediatric hematology/oncology training at St. Jude Children's Research Hospital in Memphis, Tennessee, with a focus on pediatric neuro-oncology.
Dr. DeWire's clinical and academic interests pertain to children and families affected by central nervous system tumors. She is a member of the Central Nervous System (Brain Tumor) Committee in the Children's Oncology Group (COG) as well as the Cincinnati Children's co-principal investigator for the Pediatric Brain Tumor Consortium (PBTC).
MD: Boonshoft School of Medicine at Wright State University, Dayton, OH.
Residency: Pediatrics, University of Tennessee College of Medicine.
Fellowship: Pediatric Hematology/Oncology, University of Tennessee College of Medicine and St. Jude Children’s Research Hospital.
Gass D, DeWire M, Chow L, Rose SR, Lawson S, Stevenson C, Pai AL, Jones B, Sutton M, Lane A, Pruitt D, Fouladi M, Hummel TR. Pediatric tectal plate gliomas: a review of clinical outcomes, endocrinopathies, and neuropsychological sequelae. J Neurooncol. 2015 Jan 13.
Salloum R, DeWire M, Lane A, Goldman S, Hummel T, Chow L, Miles L, Sutton M, Stevenson C, Fouladi M, Leach J. Patterns of Progression in Pediatric Patients with high-grade glioma or diffuse intrinsic pontine glioma treated with Bevacizumab-based therapy at diagnosis. J Neurooncol. 2014 Nov 30.
DeWire M, Beltran C, Boop FA, Helton KJ, Ellison DW, McKinnon PJ, Gajjar A, Pai Panandiker A. Radiation therapy and adjuvant chemotherapy in a patient with a high grade glioma and underlying DNA damage repair defect. J Clin Oncol. 2012 Jun 11.
Van Poppel M, Klimo P, DeWire M, Sanford R, Boop F, Broniscer A, Wright K, Gajjar A. Resection of Infantile Brain Tumors after neoadjuvant chemotherapy: The St. Jude Experience. J Neurosurg Pediatrics. 2011 Sept;8:251-256.
Johnson R, Wright K, Poppleton H, Murugesan M, Finkelstein D, Rand V, Leary S, White E, Eden C, Hogg T, Pounds S, Northcott P, Mack S, Neale G, Coyle B, Atkinson J, DeWire M, Gillespie Y, Allen J, Boop FA, Sanford RA, Gajjar A, Ellison DW, Taylor MD, Grundy R, Gilbertson RJ. Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature. 2010 July;466(7306):632-636.
DeWire M, Ellison D, McKinnon P, Patay Z, Sanders R, Gajjar A. Fanconi Anemia and Bi-allelic BRCA2 mutation diagnosed in a young child with an Embryonal CNS tumor. Pediatric Blood and Cancer. 2009 Dec;53(6):1140-1142.
Rachid Drissi, PhD
studies replicative senescence or cellular aging, believed to be a tumor suppressor mechanism by which normal cells limit cell proliferation to prevent genome instability and cancer. The long-term goal of their research program is to examine telomere disruption signaling to DNA damage pathway and senescence. They are also developing a combination therapy that includes telomere disruption to improve the outcome for children with brain tumors.
BS: University of Rouen, France, 1983.
MS: University of Rouen, France, 1984.
MS: University of Paris VI, France, 1988.
PhD: University of Paris VI, France, 1994.
Margol A, Robison N, Gnanachandran J, Hung LT, Kennedy R, Vali M, Muthugounder S, Dhall G, Finlay JL, Erdreich-Epstein A, Krieger MD, Drissi R, Fouladi M, Gilles FH, Judkins AR, Sposto R, Asgharzadeh S. Tumor Associated Macrophages in SHH Subgroup of Medulloblastomas. Clin Cancer Res. 2014 Oct 24.
Dorris K, Sobo M, Onar-Thomas A, Panditharatna E, Stevenson CB, Gardner SL, DeWire MD, Pierson CR, Rempel SA, Olshefski R, Goldman S, Miles L, Fouladi M, Drissi R*. Prognostic Significance of Telomere Maintenance Mechanisms in Pediatric High-Grade Gliomas. Journal of Neuro-Oncology. 2014 Jan 30. (*senior author)
Thompson PA, Drissi R*, Muscal JA, Panditharatna E, Fouladi M, Ingle AM, Ahern CH, Reid JM, Weigel BJ, Blaney SM. A Phase I Trial of Imetelstat in Children with Refractory or Recurrent Solid Tumors: A Children’s Oncology Group Phase 1 Consortium Study (ADVL1112). Clin Cancer Res. 2013 Oct 4. (*biology chair)
Sturm D, Witt H, Hovestadt V, Quang DK, Jones DTW, Konermann C, Pfaff E, Sill M, Bender S, Kool M, Becker N, Zucknick M, Hielscher T, Liu XY, Fontebasso AM, Rizhova M, Tönjes M, Albrecht S, Jacob K, Wolter M, Ebinger M, Schuhmann MU, van Meter T, Frühwald M, Hauch H, Pekrun A, Radlwimmer B, Niehues T, von Komorowski G, Dürken M, Kulozik AE, Madden J, Donson A, Drissi R, Fouladi M, Scheurlen W, von Deimling A, Monoranu C, Roggendorf W, Herold-Mende C, Unterberg A, Kramm CM, Felsberg J, Hartmann C, Milde T, Witt O, Lindroth A, Schwartzentruber J, Faury D, Zakrzewska M, Zakrzewski K, Liberski PP, Zapatka M, Hauser P, Garami M, Klekner A, Bognar L, van Sluis P, Volckmann R, Mikkelsen T, Aldape K, Reifenberger G, Collins VP, Majewski J, Korshunov A, Lichter P, Plass C, Jabado N, Pfister SM. Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of glioblastoma. Cancer Cell. 2012;22:425-437.
Drissi R*, Bockhold CA, Wu J, Dome JS*. Telomere Shortening Alters the Kinetics of the DNA Damage Response after Ionizing Radiation in Human Cells. Cancer Prev Res. 2011;4(12):1973-1981. (*joint senior author)
Kavanaugh GM, Wise-Draper TM, Morreale RJ, Morrison MA, Gole B, Shwemberger S, Tichy ED, Lu L, Babcock GF, Wells JM, Drissi R, Bissler JJ, Stambroock PJ, Andreassen PR, Wiesmüller L, Wells SI. The human DEK oncogene regulates DNA damage response signaling and repair. Nucleic Acids Res. 2011;39(17):7465-7476.
Sanders RP, Drissi R, Billups CA, Daw NC, Valentine MB, Dome JS. Telomerase expression predicts unfavorable outcome in osteosarcoma. J Clin Oncol. 2004 Sep 15;22(18):3790-7.
Drissi R*, Bakkenist CJ*, Wu J, Kastan MB, Dome JS. Disappearance of the telomere dysfunction-induced stress response in fully senescent cells. Cancer Res. 2004;64:3748-3752. (*equal contribution).
Drissi R, Zindy F, Roussel MF, Cleveland JL. c-Myc-mediated regulation of telomerase activity is disabled in immortalized cells. J Biol Chem. 2001 Aug 10;276(32):29994-30001.
Stigger E, Drissi R, Lee SH. Functional analysis of human replication protein A in nucleotide excision repair. J Biol Chem. 1998 Apr 10;273(15):9337-43.
Maryam Fouladi, MD, MSc, FRCPC Medical Director, Neuro-Oncology Program
serves as chair for the CNS Tumor New Agents/Relapse Committee for the Children’s Oncology Group, and as member of the steering committee for the COG CNS Tumor Committee and the Collaborative Ependymoma Research Network (CERN). She serves as local and national study chair for active open clinical trials that test new approaches to treat children with very poor prognosis tumors such as high-grade gliomas and diffuse intrinsic pontine gliomas.
Medical Director, Neuro-Oncology Program
Chair, Pediatric Brain Tumor Consortium Steering Committee
Cincinnati Children's Principal Investigator, Collaborative Ependymoma Research Network
Maryam Fouladi, MD, MSc, graduated from the University of Toronto School of Medicine, and completed her pediatric residency and hematology / oncology fellowship training at the Hospital for Sick Children in Toronto, Canada. Dr. Fouladi then completed her neuro-oncology fellowship training at St. Jude Children's Research Hospital, and later completed further training in the molecular pharmacology department at St. Jude before becoming a neuro-oncology faculty member in 2000. She served as the chair of the Phase I Committee at St. Jude.
Dr. Fouladi moved to Cincinnati Children's in 2008 to direct the neuro-oncology program. She is currently chair for the CNS Tumor New Agent Committee for the Children’s Oncology Group. She is a member of the steering committee for the COG CNS Tumor Committee as well as the Developmental Therapeutics group at COG, and is a member of the Collaborative Ependymoma Research Network (CERN). She serves as local and national study chair (through CERN, COG and the Pediatric Brain Tumor Consortium) for clinical trials that test new approaches to treat children with very poor prognosis tumors such as high-grade gliomas and diffuse intrinsic pontine gliomas.
BS: Human Biology, University of Toronto, Toronto, Canada, 1987.
MD: University of Toronto, Toronto, Canada, 1991.
MSc: Institute of Medical Science, University of Toronto, Toronto, Canada, 2002.
Dorris K, Fouladi M, Davies SM, Perentesis JP, Lawrence JM, Chow LM, Assa'ad A, Uygungil B, Jodele S. Severe Allergic Reactions to Thiol-based Cytoprotective Agents Mesna and Amifostine in a Child With a Supratentorial Primitive Neuroectodermal Tumor. J Pediatr Hematol Oncol. 2011 Aug;33(6):e250-2.
Phillips CL, Miles L, Jones BV, Sutton M, Crone K, Fouladi M. Medulloblastoma with melanotic differentiation: case report and review of the literature. J Neurooncol. 2011 Jul;103(3):759-64.
Fouladi M, Gururangan S, Moghrabi A, Phillips P, Gronewold L, Wallace D, Sanford RA, Gajjar A, Kun LE, Heideman R. Carboplatin-based primary chemotherapy for infants and young children with CNS tumors. Cancer. 2009 Jul 15;115(14):3243-53.
Shih C, Hale GA, Gronewold L, Tong X, Gilger EA, Srivastava DK, Kun LE, Gajjar A, Fouladi M. High-Dose Chemotherapy with Autologous Stem Cell Rescue for Children with Recurrent Malignant Brain Tumors. Cancer. Mar 15;112(6):1345-53.
Fouladi M, Nicholson S, Zhou T, Laningham F, Helton K, et al. A Phase II Study of the Farnesyl Transferase Inhibitor, Tipifarnib, in Children with Recurrent or Progressive High Grade Glioma, Medulloblastoma/PNET or Brainstem Glioma: A Children’s Oncology Group Study. Cancer. 2007 Dec 1;110(11):2535-41.
Fouladi M, Laningham F, Wu J, O’Shaughnessy M, Molina K, Broniscer A, Spunt SL, Stewart CF, Houghton PJ, Gilbertson RJ, Furman WL. Phase I Study of Everolimus (RAD001) in Pediatric Patients with Refractory Solid Tumors. J Clin Oncol. 2007 Oct 20;25(30):4806-12.
Morris B, Gajjar A, Okuma, J, Yutaka Y, Wallace D, Kun L, Merchant T, Fouladi M, Broniscer A, Robison L, Hudson M. Survival and Late Mortality in Long-term Survivors of Pediatric Central Nervous System Tumors. J Clin Oncol. 2007 Apr 20;25(12):1532-8.
Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, Woo S, Wheeler G, Ahern V, Krasin MJ, Fouladi M, Broniscer A, Krance R, Hale GA, Stewart CF, Dauser R, Sanford RA, Fuller C, Lau C, Boyett JM, Wallace D, Gilbertson RJ. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicenter trial. Lancet Oncol. 2006 Oct;7(10):813-20. Erratum in: Lancet Oncol. 2006 Oct;7(10):797.
Fouladi M, Blaney S, Young Poussaint T, Freeman B, McLendon R, Fuller C, Adesina A, Hancock M, Danks M, Ivy P, Stewart C, Gajjar A. A Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma (MB), supratentorial primitive neuroectodermal tumors (SPNET) and atypical teratoid rhabdoid tumors (ATRT): A Pediatric Brain Tumor Consortium Study. Cancer. 2006 107:2291-2297.
Fouladi M. Histone deacetylase inhibitors. Cancer Invest. 2006 (5):521-7.
Merchant T, Fouladi M. Ependymoma: New therapeutic approaches including radiation and chemotherapy. J Neuro Oncol. 2006;3:287-99.
James I. Geller, MD Medical Director, Kidney and Liver Tumors Program
focuses on children and young adults affected by solid tumors. Dr. Geller's expertise is recognized internationally, as witnessed by his appointments to the Children's Oncology Group (COG) Renal Tumor, Liver Tumor, Retinoblastoma and Central Nervous System (Brain Tumor) Committees. Dr. Geller directs and spearheads local and national studies in these areas, with an emphasis on novel therapeutics.
Medical Director, Kidney and Liver Tumors Program
Co-Medical Director, Retinoblastoma Program
Associate Director, Global Cancer Programs
Developmental therapeutics; renal / liver / retinoblastoma / neuro-oncology
James I. Geller, MD, completed his undergraduate training at Dartmouth College, graduate medical training at the Sackler School of Medicine, residency training in pediatrics at New York Medical College and pediatric hematology / oncology training at St. Jude Children's Research Hospital. His current appointment is with Cincinnati Children's Hospital Medical Center within the University of Cincinnati in the capacity of associate professor of pediatrics.
Dr. Geller's clinical and academic interests pertain to children and families affected by solid tumors, including brain tumors. Dr. Geller's expertise is recognized both nationally and internationally in the fields of retinoblastoma, renal tumors, liver tumors and brain tumors, as witnessed by his appointments to the Children's Oncology Group (COG) Rare / Retinoblastoma Committee as both a steering/voting member and as liaison to the COG Young Investigator Committee; the COG Renal Tumor Committee (RTC) as steering/voting member, RTC Sub-Committee chair of developmental therapeutics, and RTC liaison to both the COG Developmental Therapeutics Committee and the Pediatric Preclinical Testing Program Guidance Committee; and to the Central Nervous System (Brain Tumor) Committee as a voting member. Dr. Geller has been an invited speaker at numerous national and international meetings and symposia and spearheads both local and national clinical research initiatives in these areas, with an emphasis on finding new treatment options.
MD: Sackler School of Medicine, 1997.
Residency: New York Medical College, 2000.
Fellowship: St Jude Children's Research Hospital, 2004.
Certification: Pediatrics, 2000, 2007; Pediatric Hematology / Oncology, 2005.
Geller JI, Meyers AB, Towbin AJ, Serai S, Geller JI, Podberesky DJ. Characterization of pediatric liver lesions with gadoxetate disodium. Pediatr Radiol. 2011 Sep;41(9):1183-97.
Pressey JG, Wright JM, Geller JI, Joseph DB, Pressey CS, Kelly DR. Sirolimus therapy for fibromatosis and multifocal renal cell carcinoma in a child with tuberous sclerosis complex. Pediatr Blood Cancer. 2010 Jul 1;54(7):1035-7.
Cripe TP. Adenovirus gene therapy for pediatric cancers: shall we gather at the liver? Pediatr Blood Cancer. 2009 Aug;53(2):133-5.
Geller JI, Dome JS. Retroperitoneal lymph node dissection for pediatric renal cell carcinoma. Pediatr Blood Cancer. 2009 Mar;52(3):430.
Geller JI, Leslie ND, Yin H. Malignant Rhabdoid Tumor. eMedicine from WebMD. 2009 Dec. Available online.
Geller JI, Wall D, Perentesis J, Blaney SM, Bernstein M; Pediatric Oncology Group study 9376. Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376). Pediatr Blood Cancer. 2009 Mar;52(3):346-50.
Geller JI. Genetic stratification of Wilms tumor: is WT1 gene analysis ready for prime time? Cancer. 2008 Sep 1;113(5):893-6.
Geller JI, Argani P, Adeniran A, Hampton E, De Marzo A, Hicks J, Collins MH. Translocation renal cell carcinoma: lack of negative impact due to lymph node spread. Cancer. 2008 Apr 1;112(7):1607-16.
Geller JI, Dome JS. Adjuvant therapy in pediatric patients with completely resected renal cell carcinoma. Pediatr Blood Cancer. 2006 Apr;46(4):527.
Geller JI, Dome JS. Local lymph node involvement does not predict poor outcome in pediatric renal cell carcinoma. Cancer. 2004 Oct 1;101(7):1575-83.
Adrienne M. Hammill, MD, PhD Member, Division of Oncology
conducts clinical research on hemangiomas and vascular malformations, focusing on development of new therapies for these conditions and new tools for assessing response to therapy, including novel imaging modalities.
Hemangiomas and vascular malformations; genetic predispositions to cancer
Dr. Adrienne M. Hammill is trained in pediatrics and hematology/oncology and is particularly interested in bringing new and/or better medical therapy options to the treatment of vascular anomalies. She is one of the medical physicians for the Hemangioma and Vascular Malformations team. She obtained her schooling at the University of Texas Southwestern, and completed her residency and fellowship here at Cincinnati Children’s Hospital Medical Center. She is a dedicated professional and strives to improve the treatment of those she cares for. Dr. Hammill has a special interest in Sturge Weber syndrome and due to her dedicated involvement, Cincinnati Children’s has been named a site for the brain vascular malformations consortium, which is a clinical research group funded by National Institutes of Health and the rare disease network. She was nominated as a finalist for The Making a Difference Award in 2013 through the Patient Advisory Council. This nomination for staff was for their efforts to improve the patient’s experience in terms of lives saved, errors caught, kindness shown, and battles fought. A Cincinnati Children’s patient nominated Dr. Adrienne Hammill for making her feel secure and talking to her one-on-one as a friend, not a doctor.
MD: University of Texas Southwestern Medical School, Dallas, TX, 2004.
PhD: University of Texas Southwestern Graduate School of Biomedical Sciences, Dallas, TX, 2004.
Residency: Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.
Fellowship: Cincinnati Children’s Hospital Medical Center.
Certification: Pediatrics, 2008.
Trent R. Hummel, MD
focuses on developing novel therapeutics to treat children with all central nervous system tumors including those with very poor prognosis tumors such as high-grade gliomas and diffuse intrinsic pontine gliomas. Dr. Hummel is leading a national Phase 1 clinical trial investigating temozolomide in combination with vorinostat.
Neuro-oncology; CNS tumors in neurofibromatosis type 1 and 2 research interests: developing novel therapeutics in central nervous system tumors including those with very poor prognosis such as high-grade gliomas and diffuse intrinsic pontine gliomas.
Trent R. Hummel, MD, completed his graduate medical training at the University of Cincinnati College of Medicine, residency training in pediatrics at Children's Hospital Medical Center of Akron and pediatric hematology/oncology training at Cincinnati Children's Hospital Medical Center. His current appointment is at Cincinnati Children's Hospital Medical Center within the University of Cincinnati in the capacity of assistant professor of pediatrics.
Dr. Hummel's clinical and academic interests pertain to children and families affected by central nervous system tumors. He is a member of the Central Nervous System (Brain Tumor) Committee in the Children's Oncology Group (COG) as well as the Cincinnati Children's co-principal investigator for the Pediatric Brain Tumor Consortium (PBTC). Dr. Hummel focuses on developing novel therapeutics to treat children with all central nervous system tumors including those patients with neurofibromatosis type 1 and 2 related CNS tumors and very poor prognosis tumors such as high-grade gliomas and diffuse intrinsic pontine gliomas.
BS: Eastern Mennonite University, Harrisburg, VA, 1997.
MD: University of Cincinnati College of Medicine, Cincinnati, OH, 2001.
Residency: Children’s Hospital Medical Center of Akron, Akron, OH, 2004.
Fellowship: Pediatric Hematology / Oncology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2007; Research Fellow, Division of Experime